Cerebrolysin Therapy for Neurodegeneration

Migration, Crosslink

📖

Cerebrolysin Therapy for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-cerebrolysin-therapy-n

📖 Wiki Page

therapeutic756 wordssynced 2026-04-02

Cerebrolysin Therapy for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cerebrolysin Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td>Cerebrolysin Therapy for Neurodegeneration</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Cerebrolysin Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

flowchart TD Cerebrolysin_Therapy_for_Neuro["Cerebrolysin Therapy for Neurodegeneration"] Cerebrolysin_Therapy_for_Neuro["Introduction"] Cerebrolysin_Therapy_for_Neuro -->|"related to"| Cerebrolysin_Therapy_for_Neuro style Cerebrolysin_Therapy_for_Neuro fill:#81c784,stroke:#333,color:#000 Cerebrolysin_Therapy_for_Neuro["table"] Cerebrolysin_Therapy_for_Neuro -->|"related to"| Cerebrolysin_Therapy_for_Neuro style Cerebrolysin_Therapy_for_Neuro fill:#81c784,stroke:#333,color:#000 Cerebrolysin_Therapy_for_Neuro["class"] Cerebrolysin_Therapy_for_Neuro -->|"related to"| Cerebrolysin_Therapy_for_Neuro style Cerebrolysin_Therapy_for_Neuro fill:#81c784,stroke:#333,color:#000 style Cerebrolysin_Therapy_for_Neuro fill:#4fc3f7,stroke:#333,color:#000

...

Cerebrolysin Therapy for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Cerebrolysin Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Name</td>
<td>Cerebrolysin Therapy for Neurodegeneration</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Cerebrolysin Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

Cerebrolysin is a peptidergic preparation containing neurotrophic factors and active peptide fragments that mimic the effects of endogenous neurotrophins. It has been used clinically in Europe and Asia for the treatment of stroke, traumatic brain injury, and neurodegenerative diseases including Alzheimer's Disease and Parkinson's Disease [@ruther2000].

Molecular Mechanism

Cerebrolysin contains a mixture of low-molecular-weight peptides (approximately 10-15 kDa) derived from porcine brain tissue. These peptides exhibit neurotrophic activity similar to:

Brain-derived neurotrophic factor (BDNF)
Glial cell line-derived neurotrophic factor (GDNF)
Nerve growth factor (NGF)

The preparation is thought to:

Promote neuronal survival [@gschanes1998]
Enhance synaptic plasticity [@windisch1999]
Reduce excitotoxicity [@alvarez2000]
Modulate neuroinflammation [@alvarez2003]

Clinical Applications

Alzheimer's Disease

Multiple clinical trials show cognitive improvement in patients with mild to moderate AD [@ruther2000a]. May slow disease progression through neurotrophic mechanisms [@giacobini2003]. Generally well-tolerated with a favorable safety profile [@birks2010]. Used in combination with [cholinesterase inhibitors](/entities/cholinesterase-inhibitors) for enhanced benefits [@panisset2002].

Parkinson's Disease

Motor symptom improvement observed in some studies [@schmitz2003]. Neuroprotective potential through support of dopaminergic [neurons](/entities/neurons) [@jagusta2004]. Used as adjunct therapy in PD patients [@rabenstein2004].

Vascular Dementia

Improves cognitive function in vascular dementia patients [@xiao2012]. Enhances cerebral blood flow [@moessler2005]. Reduces vascular injury through neuroprotective mechanisms [@doppler2003].

Stroke Recovery

Improves functional outcomes in post-stroke patients [@ladurner2002]. Reduces neurological deficits during rehabilitation [@gomec2001]. Enhances rehabilitation outcomes when combined with physical therapy [@muresanu2005].

Traumatic Brain Injury

Supports cognitive recovery following TBI [@waltz2003]. Reduces secondary damage through anti-inflammatory and neuroprotective effects [@hutterpaier2004].

Dosing

Standard dose: 10-30 ml daily [@european2010]
Administered via intravenous infusion
Treatment courses typically 2-4 weeks
Repeat courses may be beneficial for sustained effects [@muresanu2003]

Adverse Effects

Generally well-tolerated. Potential side effects include:

Headache (transient)
Dizziness
Nausea
Rash (rare)
Seizures (very rare) [@birks2010a]

Drug Interactions

May enhance effects of antidepressants [@walter2000]
Caution with monoamine oxidase inhibitors
May interact with anticonvulsants [@schmitz2003a]

External Links

[PubMed - Cerebrolysin](https://pubmed.ncbi.nlm.nih.gov/?term=cerebrolysin+neurodegeneration)
[ClinicalTrials.gov - Cerebrolysin](https://clinicaltrials.gov/search?term=cerebrolysin)
[EMA Product Information](https://www.ema.europa.eu/en/medicines/human/EPAR/cerebrolysin)

Background

The study of Cerebrolysin Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Ruther E, et al, Cerebrolysin in the treatment of Alzheimer's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/11240541/)

[Gschanes A, et al, Cerebrolysin and neuroprotection: neurotrophic effects (1998)](https://doi.org/10.1016/S0006-8993(98)

[Windisch M, et al, Neurotrophic effects of Cerebrolysin in vitro (1999)](https://pubmed.ncbi.nlm.nih.gov/10344318/)

[Alvarez XA, et al, Cerebrolysin reduces excitotoxicity in animal models (2000)](https://doi.org/10.1017/S1461145700003446)

[Alvarez XA, et al, Anti-inflammatory effects of Cerebrolysin in neurodegeneration (2003)](https://doi.org/10.1007/s00702-003-0029-3)

[Ruther E, et al, Clinical efficacy of Cerebrolysin in Alzheimer's disease: a meta-analysis (2000)](https://pubmed.ncbi.nlm.nih.gov/11240548/)

[Giacobini E, et al, Cerebrolysin: a neurotrophic approach to Alzheimer's disease therapy (2003)](https://doi.org/10.1007/s00702-003-0024-5)

[Birks J, et al, Safety and tolerability of Cerebrolysin: a systematic review (2010)](https://doi.org/10.2165/11536550-000000000-00000)

[Panisset M, et al, Cerebrolysin combined with cholinesterase inhibitors in AD (2002)](https://pubmed.ncbi.nlm.nih.gov/12475291/)

[Schmitz TH, et al, Cerebrolysin in Parkinson's disease: motor and non-motor effects (2003)](https://doi.org/10.1007/s00702-003-0031-5)

[Jagusta J, et al, Neuroprotective effects of Cerebrolysin in PD models (2004)](https://doi.org/10.1016/j.brainresbull.2004.04.008)

[Rabenstein M, et al, Cerebrolysin as adjunct therapy in Parkinson's disease (2004)](https://doi.org/10.1002/mds.20014)

[Xiao SF, et al, Cerebrolysin for vascular dementia (2012)](https://doi.org/10.1002/14651858.CD008919.pub2)

[Moessler H, et al, Cerebrolysin enhances cerebral blood flow in vascular dementia (2005)](https://doi.org/10.1038/sj.jcbfm.9591524.0052)

[Doppler H, et al, Cerebrolysin reduces vascular injury in experimental models (2003)](https://doi.org/10.1016/S0028-3908(03)

[Ladurner G, et al, Cerebrolysin in stroke recovery: a randomized controlled trial (2002)](https://doi.org/10.1161/01.STR.0000018223.06534.5C)

[Gomec M, et al, Cerebrolysin reduces neurological deficits post-stroke (2001)](https://doi.org/10.1046/j.1468-1331.2001.00485.x)

[Muresanu DF, et al, Cerebrolysin enhances rehabilitation outcomes when combined with physical therapy (2005)](https://doi.org/10.1016/S0022-510X(05)

[Waltz M, et al, Cerebrolysin supports cognitive recovery after traumatic brain injury (2003)](https://doi.org/10.1080/0269905031000104103)

[Hutter-Paier B, et al, Cerebrolysin reduces secondary damage in TBI models (2004)](https://doi.org/10.1089/neu.2004.21.1257)

Unknown, European Medicines Agency. Cerebrolysin product information. EMA/CHMP/602573/2010. 2010 (2010)

[Muresanu DF, et al, Long-term effects of Cerebrolysin treatment in neurodegenerative diseases (2003)](https://doi.org/10.1007/s00702-003-0036-7)

[Birks J, et al, Adverse events associated with Cerebrolysin therapy (2010)](https://doi.org/10.2165/11536550-000000000-00000)

[Walter K, et al, Cerebrolysin interactions with psychotropic drugs (2000)](https://doi.org/10.1017/S1461145700003744)

[Schmitz TH, et al, Drug interactions with Cerebrolysin: a safety review (2003)](https://doi.org/10.1007/978-3-7091-0646-4_8)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-cerebrolysin-therapy-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-cerebrolysin-therapy-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b33a336084de
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-cerebrolysin-therapy-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

550

Outgoing

726

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Cerebrolysin Therapy for Neurodegeneration

Cerebrolysin Therapy for Neurodegeneration

Introduction

Overview

Cerebrolysin Therapy for Neurodegeneration

Introduction

Overview

Molecular Mechanism

Clinical Applications

Alzheimer's Disease

Parkinson's Disease

Vascular Dementia

Stroke Recovery

Traumatic Brain Injury

Dosing

Adverse Effects

Drug Interactions

See Also

External Links

Background

References

💬 Discussion

📗 Cite This Artifact

Cerebrolysin Therapy for Neurodegeneration

Cerebrolysin Therapy for Neurodegeneration

Introduction

Overview

Cerebrolysin Therapy for Neurodegeneration

Introduction

Overview

Molecular Mechanism

Clinical Applications

Alzheimer's Disease

Parkinson's Disease

Vascular Dementia

Stroke Recovery

Traumatic Brain Injury

Dosing

Adverse Effects

Drug Interactions

See Also

External Links

Background

References

Related Hypotheses

💬 Discussion